NFL Biosciences (FRA:82F) YoY EBITDA Growth: 28.11% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:82F NFL Biosciences SA FRA:82F
26 GF Score
Price €0.69
! 1 Warning Sign
View Full Analysis

What is NFL Biosciences YoY EBITDA Growth?

NFL Biosciences FRA:82F -1.58% 26 YoY EBITDA Growth is 28.11% as of Dec. 2025. GuruFocus rates FRA:82F with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. NFL Biosciences's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 28.11%.

NFL Biosciences's EBITDA per Share for the six months ended in Dec. 2025 was €-0.13.

NFL Biosciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for NFL Biosciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NFL Biosciences YoY EBITDA Growth Chart

NFL Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial -294.23 -161.95 7.08 46.09 -10.04

NFL Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.57 71.67 15.14 -92.94 28.11
FRA:82F
26GF Score
NFL Biosciences SA FRA:82F
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NFL Biosciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

NFL Biosciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.296--0.269)/ | -0.269 |
=-10.04 %

NFL Biosciences's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.133--0.185)/ | -0.185 |
=28.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 28.11% mean?
NFL Biosciences (FRA:82F) has a YoY EBITDA Growth of 28.11% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for NFL Biosciences and its competitors.
Is NFL Biosciences' YoY EBITDA Growth too high?
NFL Biosciences' current YoY EBITDA Growth is 28.11%. Overall, NFL Biosciences has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does NFL Biosciences' YoY EBITDA Growth compare to VRTX and REGN?
NFL Biosciences' YoY EBITDA Growth of 28.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for NFL Biosciences and its competitors. NFL Biosciences's current YoY EBITDA Growth is 28.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NFL Biosciences stock overvalued right now?
NFL Biosciences (FRA:82F) has a current YoY EBITDA Growth of 28.11%. The current YoY EBITDA Growth is 28.11%. NFL Biosciences' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For NFL Biosciences (FRA:82F), the current YoY EBITDA Growth is 28.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NFL Biosciences Business Description

Other Exchanges ALNFL:France
Address 199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
26GF Score

Get the complete analysis for FRA:82F

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price